Quick Answer
Intellia Therapeutics, Inc. reported Operating Income of -$440.99 million for fiscal year 2025.
Intellia Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$440.99M | +17.5% |
| 2024 | -$534.26M | -3.7% |
| 2023 | -$515.29M | -12.5% |
| 2022 | -$458.16M | -71.1% |
| 2021 | -$267.85M | -96.1% |
| 2020 | -$136.58M | -28.4% |
| 2019 | -$106.37M | -17.1% |
| 2018 | -$90.87M | -30.6% |
| 2017 | -$69.56M | -116.3% |
| 2016 | -$32.16M | -139.8% |
| 2015 | -$13.41M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$111.48M | +23.0% | -1.3% |
| June 30, 2025 | -$110.00M | +20.9% | +8.9% |
| March 31, 2025 | -$120.81M | -6.0% | +16.6% |
| September 30, 2024 | -$144.77M | -10.4% | -4.1% |
| June 30, 2024 | -$139.04M | -5.1% | -22.0% |
| March 31, 2024 | -$114.00M | -1.8% | +13.0% |
| September 30, 2023 | -$131.11M | -24.2% | +0.9% |
| June 30, 2023 | -$132.33M | -34.6% | -18.2% |
- Intellia Therapeutics, Inc. showed an increase of +17.5% in Operating Income compared to the prior fiscal year.
- Over the 2015–2025 period, Intellia Therapeutics, Inc.’s operating income has declined by 3188.8% (from -$13.41 million to -$440.99 million).
- The most recent figure is from Intellia Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: